Frankfurt
13.04.26 | 08:09
0,001 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | Nuformix PLC - Total Voting Rights | - | RNS | ||
| 11.03. | SMALL-CAP WINNERS & LOSERS: Nuformix down after GBP1.0 million placing | 2 | Alliance News | ||
| 11.03. | Nuformix PLC - £1.0 million Placing | - | RNS | ||
| NUFORMIX Aktie jetzt für 0€ handeln | |||||
| 10.03. | Nuformix erhält FDA-Orphan-Drug-Status für Behandlung von Lungenfibrose | 1 | Investing.com Deutsch | ||
| 10.03. | Nuformix receives FDA orphan drug status for IPF treatment | 1 | Investing.com | ||
| 10.03. | Nuformix PLC - Confirmation of US ODD for NXP002 in IPF | - | RNS | ||
| 03.03. | Nuformix PLC - Result of AGM | - | RNS | ||
| 05.02. | Nuformix PLC - Posting of Annual Report and Notice of AGM | - | RNS | ||
| 27.01. | Nuformix focused on lead asset for pulmonary fibrosis as loss narrows | 1 | Alliance News | ||
| 27.01. | Nuformix PLC - Annual Results for period ended 30 September 2025 | 1 | RNS | ||
| 28.11.25 | Nuformix PLC - Total Voting Rights | - | RNS | ||
| 12.11.25 | IN BRIEF: Nuformix raises GBP228,000 in open offer | 2 | Alliance News | ||
| 12.11.25 | FDA fordert von Nuformix Klärung zum Antrag auf Orphan-Drug-Status | 1 | Investing.com Deutsch | ||
| 12.11.25 | FDA requests clarification on Nuformix's orphan drug application | 1 | Investing.com | ||
| 12.11.25 | Nuformix PLC - Update re. US FDA ODD Application | - | RNS | ||
| 12.11.25 | Nuformix PLC - Results of Underwritten Open Offer | - | RNS | ||
| 29.10.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 29.10.2025 | 1.135 | Xetra Newsboard | Das Instrument 1TY NL0013654783 PROSUS NV EO -,05 EQUITY wird cum Kapitalmassnahme gehandelt am 29.10.2025 und ex Kapitalmassnahme am 30.10.2025 The instrument 1TY NL0013654783 PROSUS NV EO -,05 EQUITY... ► Artikel lesen | |
| 28.10.25 | Nuformix PLC - Underwritten Open Offer | 1 | RNS |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONANO GENOMICS | 1,150 | +1,32 % | Bionano Genomics stock price target lowered to $6 by H.C. Wainwright | ||
| TONIX PHARMACEUTICALS | 11,130 | +4,70 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and ... | Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology of TNX-1900 for craniofacial pain conditions, including migraine and trigeminal... ► Artikel lesen | |
| KHIRON LIFE SCIENCES | 0,029 | -100,00 % | Khiron Life Sciences Corp: Khiron Life Sciences warrants to expire Nov. 26 | ||
| CHRISTINA LAKE CANNABIS | 0,014 | 0,00 % | Christina Lake Cannabis Corp: Christina Lake investor Milia acquires 5.03M shares | ||
| PSYCHED WELLNESS | 0,004 | -11,11 % | Psyched Wellness Ltd.: Psyched Wellness Announces Closing of Private Placement and Shares for Debt Transaction and Resignation of a Director | Toronto, Ontario--(Newsfile Corp. - March 20, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a life sciences company focused on the production and distribution... ► Artikel lesen | |
| JAGUAR HEALTH | 0,381 | +5,37 % | Jaguar Health, Inc.: Artificial Intelligence Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure Programs | Global Market for Short Bowel Syndrome, Including Intestinal Failure (IF), Estimated to Reach $8.0 Billion by 20331AI data mining of real world clinical and symptom manifestation is beneficial in the... ► Artikel lesen | |
| MOLECULE HOLDINGS | 0,001 | 0,00 % | Molecule Holdings Inc. Provides Corporate Update | ||
| NUMINUS WELLNESS | 0,027 | -100,00 % | Numinus Wellness Inc.: Numinus Wellness Provides Update Regarding Listing Status | Vancouver, British Columbia--(Newsfile Corp. - March 24, 2026) - Numinus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,031 | 0,00 % | Betterlife Pharma Inc (2): Betterlife issues 600,000 shares to corporate adviser | ||
| MEDIPHARM LABS | 0,037 | -11,90 % | MediPharm Labs Corp.: MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue | FY 2025 revenue of $45.1 million, an increase of 8% over 2024International Medical Cannabis revenue increased 43% year-over-year and represented more than 50% of total revenueIncreased cash balance... ► Artikel lesen | |
| PROMINO NUTRITIONAL SCIENCES | 0,017 | 0,00 % | Promino Nutritional Sciences, Inc.: Promino Nutritional Sciences Launches NCAA Division I Athlete Platform Through Multi-Sport NIL Partnership with Virginia Military Institute | Burlington, Ontario--(Newsfile Corp. - April 9, 2026) - Promino Nutritional Sciences, Inc. (CSE: MUSL) (OTC: MUSLF) (FSE: 93X) ("Promino" or the "Company"), a developer of advanced proprietary amino... ► Artikel lesen | |
| ADDEX THERAPEUTICS | 0,046 | +1,11 % | Addex Therapeutics: Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment | Data published in Molecular Psychiatry
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, February 3, 2026
-
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage... ► Artikel lesen | |
| ARGENT BIOPHARMA | 0,012 | +9,09 % | ARGENT BIOPHARMA LIMITED: Completion of CannPal Asset Acquisition and Neuvis Option | ||
| CANNABIST COMPANY | 0,025 | -100,00 % | Cannabist Co Holdings Inc. - 8-K, Current Report | ||
| IANTHUS CAPITAL | 0,001 | 0,00 % | iAnthus Capital Holdings, Inc.: iAnthus Reports Fiscal Fourth Quarter and Full Year 2025 Financial Results | NEW YORK and TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- iAnthus Capital Holdings, Inc. ("iAnthus" or the "Company") (CSE: IAN, OTCID: ITHUF), which owns, operates, and partners with regulated cannabis... ► Artikel lesen |
Das Unternehmen NUFORMIX PLC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,001 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NUFORMIX PLC finden Sie auf Wallstreet Online.